Eris Lifesciences Ltd vs Glenmark Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1371 as of 06 May 15:30 . The P/E Ratio of ERIS Lifesciences Ltd changed from 23.1 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 18.86% over 5 yearsThe P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 13.5 on March 2021 to 41.5 on March 2025 . This represents a CAGR of 25.18% over 5 years The Market Cap of ERIS Lifesciences Ltd changed from ₹ 8207 crore on March 2021 to ₹ 19287 crore on March 2025 . This represents a CAGR of 18.64% over 5 yearsThe Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 13108 crore on March 2021 to ₹ 43458 crore on March 2025 . This represents a CAGR of 27.09% over 5 years The revenue of ERIS Lifesciences Ltd for the Dec '25 is ₹ 807.59 crore as compare to the Sep '25 revenue of ₹ 795.5 crore. This represent the growth of 1.52% The revenue of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 3945 crore as compare to the Sep '25 revenue of ₹ 6247 crore. This represent the decline of -36.85% The ebitda of ERIS Lifesciences Ltd for the Dec '25 is ₹ 264.51 crore as compare to the Sep '25 ebitda of ₹ 291.3 crore. This represent the decline of -9.2% The ebitda of Glenmark Pharmaceuticals Ltd for the Dec '25 is ₹ 729.88 crore as compare to the Sep '25 ebitda of ₹ 1175 crore. This represent the decline of -37.89% The net profit of ERIS Lifesciences Ltd changed from ₹ 89.55 crore to ₹ 108.83 crore over 7 quarters. This represents a CAGR of 11.79% The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 340.24 crore to ₹ 403.23 crore over 7 quarters. This represents a CAGR of 10.19% The Dividend Payout of ERIS Lifesciences Ltd changed from 21.3 % on March 2021 to 129.35 % on March 2025 . This represents a CAGR of 43.44% over 5 yearsThe Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 4.28 % on March 2021 to 4.38 % on March 2025 . This represents a CAGR of 0.46% over 5 years .

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007.
Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
Its branded generics business has a significant presence in markets across emerging economies including India.

FAQs for the comparison of ERIS Lifesciences Ltd and Glenmark Pharmaceuticals Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Glenmark Pharmaceuticals Ltd?

Market cap of ERIS Lifesciences Ltd is 19,001 Cr while Market cap of Glenmark Pharmaceuticals Ltd is 66,987 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Glenmark Pharmaceuticals Ltd?

The stock performance of ERIS Lifesciences Ltd and Glenmark Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Glenmark Pharmaceuticals Ltd?

As of May 6, 2026, the ERIS Lifesciences Ltd stock price is INR ₹1371.5. On the other hand, Glenmark Pharmaceuticals Ltd stock price is INR ₹2373.75.

How do dividend payouts of ERIS Lifesciences Ltd and Glenmark Pharmaceuticals Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Glenmark Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.